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Abbreviations: 
 
HDV   hepatitis delta virus 
HD-Ag  hepatitis D antigen 
Anti-HDV  antibody to hepatitis delta virus 
Anti-HD IgG IgG antibody to hepatitis delta virus 
Anti-HD IgM IgM antibody to hepatitis delta virus 
HDV-RNA  hepatitis delta virus genome 
HDV-1,2,3  hepatitis delta virus genotypes 
CHD   chronic hepatitis delta 
HBV   hepatitis B virus 
HBsAg  hepatitis B surface antigen 
Anti-HBc  antibody to hepatitis B core 
Anti-HBc IgM IgM antibody to hepatitis B core 
HBeAg   hepatitis B e antigen 
Anti-HBe  antibody to hepatitis B e antigen 
cccDNA  covalently closed circular DNA 
pgRNA  pregenomic RNA 
HBV-D,A,B,C,F hepatitis B virus genotypes 
HCV   hepatitis C virus 
HIV   human immunodeficiency virus 
AIDS   acquired immune deficiency syndrome 
PEG-IFN  pegylated interferon 
LAM   lamivudine 
ADV   adefovir 
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Abstract 
 
The first step in the diagnosis of Hepatitis Delta Virus Infection is testing HBsAg-
positive individuals for the antibody to the HD antigen (anti-HD). 
In anti-HD-positive subjects, the next step is testing for HDV-RNA in serum to determine 
whether the antibody reflects an ongoing active HDV infection (HDV-RNA positive) or 
represents a serological scar to past HDV infection (HDV-RNA negative). In the HDV-
positive individual with liver disease, it is critical to distinguish acute HDV/HBV coinfection 
from chronic HDV superinfection in HBsAg carriers; the course, prognosis and management 
of the two conditions are different. The differential diagnosis can be achieved through the 
scrutiny of the battery of HDV and HBV markers, which combine in patterns characteristic 
for each condition. 
Standardized competitive and m-capture commercial assays are available to determine the 
IgG and IgM antibody to HDV. Several in-house assays were developed to determine HDV-
RNA in serum; the sensitivity threshold of current PCR-based assays is 10 copies of HDV-
RNA/ml. 
Unfortunately, HDV-RNA assays are not yet standardized and the results from different 
laboratories often are not comparable due to different sensitivities. The development of an 
International reference HDV-RNA standard remains an unmet diagnostic need. 
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Introduction 
 
Indicative of HDV infection are the replication of the viral RNA with the expression 
of the HD-Antigen (HD-Ag) and the specific immune reaction of the infected host (1). In the 
immunocompetent host, HDV infection elicits an antibody response to the HD-Ag (anti-
HD), first of IgM then of IgG class (2). Active HDV infection is diagnosed on the finding of 
the HDV-RNA in serum and/or the HD-Ag in serum and liver. 
As hepatitis D results from a double infection with the HBV, the virologic assessment 
requires the consideration not only of HDV but also of the concomitant HBV infection. In 
the clinical setting efforts to diagnose HDV infection are appropriate only in the presence of 
the HBsAg in serum; HBsAg-negative patients do not harbour productive HDV infections. 
This review summarizes the virologic profiles diagnostic of HDV infections and 
provides an analysis of each marker, relevant to the diagnosis of hepatitis D. 
 
Serologic patterns of HDV infection 
 
The HDV is acquired either through simultaneous coinfection with the HBV by HBV 
naïve individuals or through superinfection on a pre-existing and persisting HBV state i.e. on 
individuals carrying the HBsAg (3). The clinical outcome is different, coinfection usually 
runs, a self-limited course that terminates with the clearance of HBV/HDV, superinfection 
usually induces a chronic hepatitis D that advances to cirrhosis and liver failure.  
The distinction of coinfection from superinfection is critical to the management and 
prognosis; it is made possible by the scrutiny for HDV and HBV markers, which discloses 
serologic patterns typical for the two conditions (fig. 1). 
 
In coinfection (fig. 1A) the expression of HDV is determined by the virulence of the 
concomitant HBV infection (4). With diminished HBV virulence, HDV expression is short-
lived, viremia transient and the anti-HD response brief or abortive. Coinfections with large 
HDV expression exhibit a full serological pattern, consisting of early viremia and HD 
antigenemia, followed by seroconversion first to IgM and then to IgG anti-HD; HD-Ag is 
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expressed in liver and the HD-RNA peaks to high titers in serum. The antibody response 
may be delayed for several days; therefore prolonged monitoring for antibodies to HDV is 
required to exclude or confirm HDV infection in patients with an acute HBsAg-positive 
hepatitis. The IgM antibody to the core antigen of the HBV (IgM anti-HBc) as well as HBV-
DNA are present in high titers; the HBeAg may also be detectable at onset of disease, but 
rapidly clears from serum followed by seroconversion to anti-HBe. 
Atypical patterns of acute coinfection were reported in hepatitis D occurring among 
drug addicts (5). In some patients, strong and early repression of HBsAg resulted in an 
HBsAg-seronegative hepatitis with positive HDV serology, followed by the return of the 
HBsAg after the clearance of HDV (6); in a few patients, superinfection terminated the 
HBsAg state with seroconversion to anti-HBs (7). In a recent single case report, acute 
hepatitis D has terminated also chronic HCV infection (8). In other patients coinfection run a 
byphasis course, with two hepatitis bouts accompanied by sequential expression of either the 
HBV or HDV (9-10).  
 
In superinfection, the virological pattern is more uniform. HDV-viremia appears early 
and the IgM and IgG anti-HD response is brisk (11). Both antibodies rapidly increase in 
superinfection progressing to cronicity and remain detectable in high titers along with the 
persistence of viremia and the progression to chronic hepatitis D (CHD); in the liver, the 
nuclei of hepatocytes are loaded with HD-Ag.  
In most of the patients replication of HBV is repressed; serum HBV-DNA is null or present 
at low titers. The IgM anti-HBc is usually negative (Fig. 1B) (12). The patterns diagnostic of 
the various clinical forms of HDV infection are summarized in table 1. 
 
The role of quantitative HBsAg testing in CHD remains under investigation. A 
correlation was observed between the decrease in serum of HBsAg and the decline of serum 
HDV-RNA in patients treated with Peg-IFN or with lamivudine; levels of HBsAg decreased 
also in patients treated with Peg-IFN in combination with Adefovir but not in patients treated 
with Adefovir monotherapy (13). The decrease of serum HBsAg might provide a valuable 
marker prognostic of the decline and ultimate clearance of HDV infection (14).  
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Antibodies to HDV 
a) IgG anti-HD 
Total antibodies to HDV are detected with a Enzyme Linked Immunosorbent Assays 
(ELISA). Commercial tests are available (ETI-AB-DetlaK-2 Sorin, Saluggia, Italy; Abbott 
IgM anti-HD). The method is a simultaneous competitive assay. The format includes a solid-
phase (plastic wells) coated with recombinant HDAg, test sample, anti-HD negative control, 
an enzyme tracer (anti-HD-Fab human-conjugated with horseradish peroxidase) and a 
chromogen substrate to develop the colour of the enzyme tracer that binds to the solid phase. 
Anti-HD in the sample and labelled anti-HD compete for the fixed quantity of HDAg bound 
to the solid phase; the amount of enzyme activity bound to the solid phase is inversely 
proportional to the concentration of anti-HD in the sample.  
Competitive assays measure all types of antibodies to HDV; however, antibodies other 
than IgG are a minority of the total reactivity and in practice the measure of total antibodies 
by competitive assays is synonymous with the measure of IgG antibodies (2, 12). The IgG 
antibody is not protective; it is present in all immunocompetent patients with HDV infection, 
coexisting with active HDV infection and hepatitis D, and may not be raised in 
immunocompromised patients who acquire HDV such as patients with AIDS (15). The IgG 
antibody is usually short-lived in coinfected patients who clear HBV-HDV. Exception are 
the drug addicts; in a retrospective analysis of blood from 27 Swedish drug addicts drawn 5-
13 years after the acute episode of HDV coinfection, 26 were clear-cut positive and one still 
gave a borderline positive result for anti-HD (16). 
Anti-HD may persist for years as a serological scar in superinfected patients who clear 
HDV infection and remain HBsAg-positive; rarely it was also detected in HBsAg-negative 
subjects, who were superinfected in the past and cleared HBV with the loss of the HBsAg 
(17). 
 
 
b) IgM anti-HD 
 
The IgM antibody to HDAg (IgM anti-HD) is measured with m-capture 
immunoassays; titration is made by tenfold dilutions (18). Assays are available 
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commercially( ETI-Delta-IgM-K2 assay, Sorin, Saluggia, Italy; anti-HD EIA Abbott, Anti-
HD IgM Kit, Serono, Italy). In chronic infection the antibody is composed mainly of 
monomeric 7S IgM molecules while 19 S pentameric molecules are prevalent in primary 
HDV infection (19). 
The IgM anti-HD is considered a marker of HDV-induced liver disease and may be a 
useful surrogate to determine HDV replication if molecular tests for HDV RNA are not 
available. The decrease and clearance of this antibody in chronic hepatitis D is a predictor of 
spontaneous or therapy –induced disease remission (2,20,21). In 38 Italian HDV patients 
treated with Peg-Interferon and Ribavirin, all positive for IgM anti-HD at baseline with a 
mean titer of 104, the antibody titer remained unchanged in virologic non-responders and in 
those in whom HDV-RNA decreased but did not clear from serum; in 5 patients who cleared 
HDV-RNA the mean antibody titer diminished by 1 log10 and it disappeared in 2 patients 
who achieved a sustained response 6 months off from therapy (22). 
 
The HD-Antigen 
The HD Antigen is expressed in the liver cell nuclei where it can be detected by 
immunochemistry (2,4). With the advent of molecular assays for HDV-RNA in serum, tissue 
immunochemistry has become obsolete (23); it requires an invasive liver biopsy and is less 
sensitive than molecular assays. The percentage of cells expressing HDAg diminishes with 
the progression of chronic hepatitis D to cirrhosis making immunohistologic testing 
inaccurate in patients with advanced disease. It can be used for the diagnosis of active HDV 
infection if molecular tests for HDV-RNA are not available.  
After disruption of the HDV virion with detergent, the HD-Antigen is exposed and can 
be measured in serum with assays based on its capture by anti-HD fixed in a solid phase and 
subsequent binding to it of anti-HD conjugated with an enzyme tracer (2,12). Commercial 
assays are available  (ETI-Delta-2, Sorin, Saluggia, Italy; HDAg Sanofi, Pasteur). However, 
immunocompetent patients exposed to HDV invariably develop in a short-while anti-HD, 
which binds and masks the serum antigen released from the virion, rendering it unavailable 
to the format. Serum HD antigen is detectable only transiently in blood specimens collected 
early at the onset of hepatitis D, before the rising of antibodies, and its finding is therefore 
diagnostic of primary HDV infection. Occasionally the HDAg can be detected for long in 
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serum of patients with an impaired immune system who do not raise antibodies, such as 
patients with AIDS or transplanted patients under pharmacological immunosuppression 
(15,24). 
 
 
HDV RNA 
 
Serum HDV-RNA was first determined with nucleic acid hybridization assays that 
used the cloned HDV genome or cDNA constructs of it (25). With the advent of Reverse 
Transcription (RT) - PCR techniques, HDV RNA has been measured with qualitative or 
semiquantitative RT-PCR assays. Sensitivity has markedly improved, with current detection 
limits of 1000 genome/ml for simple PCR and of 10 genome/ml for nested PCR (26) (fig. 2). 
A first method for the quantitation of HDV-RNA, based on the application of Real-Time 
PCR technique, has been described by Yamashiro in 2004 (27). In this assay, primers are 
designed on the template of the HD-Ag coding region; this is a highly conserved region with 
a homology of 98% between genotype 1 and genotype 2. In the assay of Le Gal (28) the 
design of primers and probe is targeted to a conserved region, located within the ribozyme. 
The assay allows the detection of all HDV genotype; a further forward primer specific for 
HDV 3 genotype was used to determine HDV-3 infection. With the procedure described by 
Hoffmann (29), genotype 1 can be distinguished from genotype 3 by the analysis of the 
results from a melting curve performed after the polymerase chain reaction. Mederacke has 
established an in-house real-time PCR assay, exploiting the utility channel of the Cobas 
TaqMan apparatus (Roche Diagnostics) (30); the use of a real-time PCR platform, in 
association with a system for the automatic extraction of RNA, provides more reproducible 
results. In the assay developed by Pollicino (31), HDV-RNA has also been quantified by real 
-time PCR with the utility channel of Cobas TaqMan instruments; with this assay, HDV -
RNA can be quantified in serum and in liver. Table 2 and 3 report the principal technical 
features of in-house Real Time PCR methods and of commercial assays published in the last 
decade. 
Unfortunately the results from different laboratories are often not comparable due to 
the diverse sensitivity of the assays; variance is caused by the use of different set of primers 
 10 
and by the variability of the RNA region amplified. 
To reduce false negative results and optimize specificity for all HDV genotypes, primers and 
probes should be targeted to the most highly conserved regions, located within the ribozyme. 
The standards utilized in different assays are heterogeneous; they include synthetic HDV-
RNA, HDV cDNA plasmid, serum from HDV infected patients or Armored RNA (complex 
of MS2 bacteriophage coat protein and RNA). With a cDNA standard it is not possible to 
check the reverse transcription step while simple optical density measurements are not 
sufficient to quantify synthetic RNA standards, whose performance is variable for the 
presence of secondary structures different from natural HDV-RNA. To calibrate quantitative 
assays, it would be desirable that WHO develops an HDV-RNA reference preparation 
quantified in International Unit and makes it available as an international standard. 
HDV-RNA quantification does not seem to correlate with the clinical stage of liver 
disease (3). It is useful to monitor treatment response in patients undergoing antiviral therapy 
and may be useful in longitudinal studies to assess the dynamics of HDV replication over 
time in infections with other hepatitis viruses. 
 
HDV Genotypes 
 
Eight major clades of HDV-RNA have been identified, differing each other for about 
40% of the nucleotide sequence (32). Genotypes may be determined by Restriction Fragment 
Length Polymorphism (RFLP) analysis or by direct sequencing (33). Genotyping is currently 
performed only in research laboratories. It has been valuable in tracing source and spreading 
of HDV infection (34); in areas where both genotypes 1 and 2 are present, it may help to 
identify patients infected with genotype 1, which has a worse outcome than genotype 2. In an 
Italian cohort (31), 21 HDV patients were infected with HDV-1 and HBV genotype D; 
among 22 HBV-monoinfected controls, genotype HBV-D was found in 18, genotype HBV-
A in 4, genotype HBV-C in 1. The genotype of HBV seems to have no clinical relevance in 
the context of HDV infection, with the exception of the combination of HBV genotype F and 
HDV genotype 3 in South America, which was correlated with severe forms of hepatitis D 
(35). In the Western world the prevalent HDV-1 genotype combines with genotype D, A and 
C without clinical differences; new HBV genotypes incoming with immigration, such as 
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genotype B from China and genotype E from sub-Saharian Africa are unlikely to have an 
impact in the clinical expression of HDV infection. 
 
IgM antibody to the Hepatitis B core antigen (IgM anti-HBc) 
The IgM anti-HBc is a surrogate marker of liver disease induced by HBV replication and its 
determination is useful to distinguish whether an acute HDV-positive hepatitis is caused by 
HBV-HDV coinfection (IgM anti-HBc positive) or by HDV superinfection in an inactive 
HBsAg carrier (IgM anti-HBc negative) and whether the concomitant chronic HBV infection 
is also pathogenic in CHD (IgM anti-HBc positive) (2,4).  
 
 
Interactions of HDV with HBV, HCV and HIV 
Due to the dominance of HDV over HBV, the majority of patients with CHD have in 
serum anti-HBe and null or low HBV-DNA. Exceptions are drug-addicts and immigrants; a 
fair proportion have fresh CHD accompanied by active HBV infection with serum HBeAg 
and consistent levels of HB viremia (3).  
Triple infections with HBV/HDV/HCV are common in drug addicts. In Germany, 
29% of a total of 254 HDV patients were also positive for anti-HCV (36). Most of the 
German-born patients were drug-addicts and 54 % had antibody to HCV; only 8% of the 
HDV patients born in Turkey and 24% of those born in Eastern Europe had anti-HCV.   
In multiple viral infections (HDV/HBV/HCV/HIV), HDV is usually dominant and inhibits 
the others viruses.  In the study of the European cohort of HIV (EuroSIDA) (37), anti-HD 
was detected in 62 (14.5%) of 422 HBV/HIV; serum HDV-RNA was detectable in 87% the 
antibody positive patients with a median titer of 1.76x107 copies/ml. Infection with HDV 
was associated with a severe chronic hepatitis/cirrhosis and a consistent mortality risk.         
In multiple infections viral dominance may change and alternate over time, with serum 
HBV-DNA and HCV-RNA reaching occasionally high levels. In a bimonthly surveillance of 
the levels of HDV/HBV/HCV during 12 months in 15 Italian patients with triple infection 
(38), 8 exhibited alternating peaks of HBV and/or/HCV replication. Similar fluctuations 
were observed in HDV cohorts form Germany and Spain and (3,39), suggesting that serum 
levels of HDV, HBV and HCV should be measured longitudinally in order to tailor antiviral 
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therapy.  
 
Liver HDV-RNA  
HDV-RNA can be detected in liver with qualitative Northern hybridization assays 
(25). The advent of qPCR technology has provided quantitative assays for the measure of 
nucleic acids in small biopsy samples, overcoming the limitation of sufficient material for 
the extraction; however, the need for an invasive liver biopsy restricts the clinical use of this 
procedure. The molecular interplays of HDV and HBV were investigated in serum and liver 
with sensitive qPCRs in 21 coinfected HDV/HBV patients and in 22 HBV-monoinfected 
patients (31). In HDV patients the median level of serum HBV-DNA was 5 log10, and of 
intrahepatic relaxed-circular DNA and cccDNA was 2 log10, significantly lower than in 
HBV-monoinfected. Although pgRNA and pre-S/S RNA in liver were also diminished (by 1 
log10) in HDV-patients, the serum HBsAg concentration was comparable between the two 
groups; large deletions in the basal core promoter/precore region were detected in 5 HDV 
patients, all of whom had low levels of serum HBV.  
These findings provide a molecular basis to the discrepancy between the biological 
help that HDV requires from HBV and the repression that it regularly exerts on the helper 
virus; the HDV is smart enough to selectively suppress some HBV functions while 
maintaining the capacity of HBV to synthesize the large amounts of envelope proteins 
necessary to the formation of HDV virions and to virus survival.  
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Legends 
 
Fig. 1A 
Serological pattern of  HDV/HBV coinfection: in severe HDV infection appear an early 
viremia and HD antigenemia followed by a seroconversion first to IgM and then to IgG 
antibodies to HDV. Simultaneously there is the expression of HBsAg and a primary 
response to HBV highlighted by the presence of IgM anti-HBcAg. 
 
 
Fig. 1B 
Serological pattern of HDV superinfection evolving to chronicity: HDV-RNA in serum 
appears early followed by a sudden IgM and IgG antibodies appearance. In most cases 
HBV replication is low or repressed and IgM antibodies to HBc antigen are negative. 
 
Fig. 2      
Increase of HDV-RNA sensitivity with the different tests developed over the last 30 
years 
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Table I: Serum patterns diagnostic of the different clinical forms of HDV infection  
 
 
HDV Markers HBV Markers 
Serum anti-HDV IgM 
anti-HDV 
IgG HDV-RNA HBsAg HBeAg anti-HBe anti-HBc IgM HBV-DNA 
Acute Hepatitis 
 
▪ Coinfection 
 
▪ Superinfection 
+ + + + + - + 
+ (> 20.000 
IU/ml) 
+ + + + - + - / +- 
- / +-         
(<2.000 
IU/ml) 
Chronic 
Hepatitis + + 
+ (105 – 107 
copies/ml)  + - + - 
- / +- 
(<2.000 
IU/ml)  
Chronic active 
HDV/HBV 
Hepatitis 
+ + + (10
5 – 107 
copies/ml) + - + - 
+ (>2.000 
IU/ml) 
Cirrhosis + / - + + / - (10
3 – 107 
copies/ml) + - + - 
- / +-
(<2.000 
IU/ml) 
HDV recovery - + - + - + - 
- / +- 
(<2.000 
IU/ml) 
 
Liver HDAg HDV-RNA HBsAg HBcAg HBV-DNA 
 
 
Chronic 
Hepatitis + + + - / + - / + 
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Table II: principal technical features of  published in-house Real Time PCR methods for HDV-RNA quantification 
 
 
 
METHODS HDV-RNA EXTRACTION 
REVERSE 
TRANSCRIPTION TARGET REGION 
GENOTYPES 
DETECTED 
REAL-TIME 
PCR 
INSTRUMENT 
STANDARD LINEARITY LIMIT OF DETECTION 
Yamashiro et al., J 
Infect Dis. 2004; 189: 
1151-7 
Acid guanidium phenol-
chloroform method 
Random hexamers (Takara Bio) 
RNase inhibitor (Promega) 
MMLV Reverse Trancriptase 
(Gibco) 
HDAg-coding region 
Primer 1164 
nt 1164-1192 
Primer 1297 
nt 1297-1268 
1, 2a, 2b 
Light Cycler System 
(Boehringer 
Mannheim) 
Synthetic HDV-RNA 
standard 
103 – 109 copies 
RNA/ml 10
3 copies RNA/ml 
Le Gal et al., 
J Clin Microbiol 2005; 
43: 2363-9 
QIAamp MinElute virus 
vacuum (Qiagen) 
Random Primers 
RNase inhibitor (Promega) 
SuperScript Reverse 
Transcriptase II (Life 
Technologies) 
Ribozyme region 
Delta-F/ T3-Delta-F 
nt 693-709 
Delta-R 
nt 891-907 
Delta-P 
nt 858-872 
 
1-7 
ABI PRISM 7000 
(Applied 
Biosystems) 
Plasmid pCRII-dFr45-R’1 103 – 109 copies /ml 102 copies/ml 
Erhardt et al., Liver 
Int 2006; 26: 805-10 
MagNA Pure Compact 
Nucleic Acid Isolation 
Kit I (Roche 
Diagnostics) 
One Step HDAg-coding region 1-3 Light Cycler System 
Patient serum calibrated 
on HDV plasmid pSVL 
LD3 
nr 1,5x102 copies/ml 
Sheldon et al., 
Antiviral  Therapy 
2008; 13: 97-102 
QiaAMP viral RNA 
extraction kit (Qiagen) 
AMV Reverse Transcriptase 
(Promega) 
nr 
 nr 
Light Cycler PCR 
thermocycler 
(Roche) 
DeltaF-R2 PCR DNA 
fragment cloned into a 
pGEMT vector 
10-1 – 108 copies/ml 102 copies/ml 
Zachou et al., Liver Int 
2009; 430-7 nr nr nr 1 nr HDV-cDNA plasmid 1,1x10
2 -1,1x105 copies 1,2x102 copies/ml 
Mederacke et al., J 
Clin Microbiol 2010; 
48: 2022-29 
TINAI kit (Roche) One step 
HDAg-coding region 
F1: nt 837-853 
F2: nt 837-854 
R: nt 891-907 
P: nt 858-872 
nr Cobas TaqMan 48 (Roche Diagnostics) 
cDNA clone in a pSVL 
expression vector 
3x102 – 1,5x108 
copies/ml 3x10
2 copies/ml 
Schaper et al., J 
Hepatol 2010; 52: 658-
64 
nr One step 
HDAg-coding region 
Primer DP1: nt 887 
Primer DP2: nt 993 
Probe HDV-FL: nt 921 
Probe HDV-LC: nt 947 
1 LightCycler system (Roche) 
Quantified serum from a 
chronic hepatitis Delta 
patient 
103 – 107 HDV-RNA 
equivalent/ml 10
3 equivalent/ml 
Hofmann et al., Diagn 
Microbiol and Infec 
Dis 2010; 67: 172-9 
QiaAMP Viral RNA 
mini Kit (Qiagen) 
Primer Random (Roche) 
SuperScript III RT (Invitrogen) 
HDAg-coding region 
Primer HD10: 
nt 469-485 
Primer HD11: 
nt 839-819 
Probe HD LNA: 
nt 703-720 
Probe HD 13R: 
nt 722-740 
Opportunity to 
identify  HDV-3 by 
subsequent melting 
analysis 
LightCycler 2.0 
instrument (Roche) Plasmid pSC-A HDV-1 2x10
3 – 108 copies/ml 2x103 copies/ml 
Pollicino et al., J.Virol 
2011; 85: 432-9 
TRIzol reagent 
(Invitrogen) 
Oligo(dt)primers 
SuperScript Reverse 
Transcriptase kit 
(Invitrogen) 
Primer DELTAF: 
nt 1063-1081 
Primer DELTAR: 
Nt 1236-1216 
Probe DELTA/FL: 
nt 1086-1108 
Probe DELTA/LC: 
nt 1113-1137 
1 Cobas TaqMan 48 (Roche Diagnostics) Plasmid pCRII-delta-R0 
1x101 – 1x107 
copies/ml 1x10
1 copies/ml 
 
nr : not reported 
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Table III: principal technical features of commercial assay for HDV-RNA quantification 
 
 
ASSAYS HDV-RNA EXTRACTION 
REVERSE 
TRANSCRIPTION 
TARGET 
REGION 
GENOTYPES 
DETECTED STANDARD LINEARITY 
LIMIT OF 
DETECTION 
RoboGene 
HDV RNA 
Quantifcation 
kit 
INSTANT Virus 
RNA Kit, version 
HDV (AJ 
Innuscreen) or 
QIAmp Viral RNA 
Mini Kit (Qiagen) 
One Step 
HDAg-
coding 
region 
1 - 8 
Synthetic 
HDV HDag 
RNA 
1x101 – 1x107 
copies/run 
 
 
1x101 
copies/run 
 
 
DIA.PRO 
HDV RNA 
Quantitation 
 
QIAmp Viral RNA 
Mini Kit (Qiagen) 
RNA 
retrotranscription Kit nr nr 
External 
standard curve 
103 – 1012 
copies/ml 1 copies/ml 
PrimerDesign 
Quantification 
Kit for HDV 
genomes 
nr 
PrimerDesign 
Precision Reverse 
Transcription kit 
HDAg-
coding 
region 
1 -7 
Positive 
control 
template to 
generate a 
standard curve 
1x102 – 1x108 
copies/ml 
1x102  
copies/ml 
 
nr : not reported 
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Fig.1A
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Fig.1B
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101 102 103 104 105 106 107 108
cDNAs (pKD3-pKD4)
RNAs (pD4-pHDV1)
RT-PCR
HDV copies/ml
1983
1984
1989
1994
2004 - 2012
NESTED-PCR
REAL-TIME PCR
HDV-RNA assays
qHDV-RNA assays  (dinamic range 101 – 108 copies/ml)
Year of introduction
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